Skip to content

PHARMA-BIO SERV, INC.: 10-K filed 2020-01-29

What PHARMA-BIO SERV, INC. reported in its annual report filed 2020-01-29 (fiscal FY 2019): 36 published measures, 74 facts as tagged in accession 0001654954-20-000889.

This filing

Form
10-K (annual report)
Filed
2020-01-29
Fiscal period
fiscal FY 2019
Accession
0001654954-20-000889 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PHARMA-BIO SERV, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2019-10-3126,633,075USD
At 2018-10-3125,378,312USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2019-10-316,025,569USD
At 2018-10-315,114,649USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2019-10-3120,607,506USD
At 2018-10-3120,263,663USD
At 2017-10-3120,747,286USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2019-10-3115,490,174USD
At 2018-10-3116,029,920USD
At 2017-10-3111,591,548USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2018-11-01 to 2019-10-312,087,256USD365
2017-11-01 to 2018-10-311,279,734USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2018-11-01 to 2019-10-31-2,207,739USD365
2017-11-01 to 2018-10-313,718,684USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2018-11-01 to 2019-10-3157,379USD365
2017-11-01 to 2018-10-31122,009USD365

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2018-11-01 to 2019-10-3119,506,911USD365
2017-11-01 to 2018-10-3117,797,425USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2018-11-01 to 2019-10-31-155,577USD365
2017-11-01 to 2018-10-31-1,799,224USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2018-11-01 to 2019-10-311,836,134USD365
2017-11-01 to 2018-10-31-116,009USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2019-10-3119,473,069USD
At 2018-10-3119,111,111USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2018-11-01 to 2019-10-3123,054,653shares365
2017-11-01 to 2018-10-3123,080,995shares365

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2018-11-01 to 2019-10-3123,113,857shares365
2017-11-01 to 2018-10-3123,096,252shares365

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2018-11-01 to 2019-10-31135,994USD365
2017-11-01 to 2018-10-312,785,525USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2019-10-31290,658USD
At 2018-10-31298,020USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2018-11-01 to 2019-10-3134,120USD365
2017-11-01 to 2018-10-3151,642USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2018-11-01 to 2019-10-312,087,256USD365
2017-11-01 to 2018-10-31-1,261,736USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2019-10-3125,974,980USD
At 2018-10-3123,411,797USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2019-10-313,670,540USD
At 2018-10-312,565,672USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2019-10-318,781,026USD
At 2018-10-315,193,385USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2018-11-01 to 2019-10-3187,891USD365
2017-11-01 to 2018-10-3156,525USD365

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2018-11-01 to 2019-10-316,176,616USD365
2017-11-01 to 2018-10-315,686,807USD365

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2018-11-01 to 2019-10-3113,330,295USD365
2017-11-01 to 2018-10-3112,110,618USD365

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2018-11-01 to 2019-10-314,479,933USD365
2017-11-01 to 2018-10-314,598,545USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2019-10-3122,995,881shares
At 2018-10-3123,058,413shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2019-10-31143,600USD
At 2018-10-31107,947USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2019-10-31799,933USD
At 2018-10-31794,973USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2019-10-31509,275USD
At 2018-10-31496,953USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2019-10-31367,437USD
At 2018-10-31418,495USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2019-10-3117,950USD
At 2018-10-3117,950USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2018-11-01 to 2019-10-312,223,250USD365
2017-11-01 to 2018-10-311,523,789USD365

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2018-11-01 to 2019-10-312,122,909USD365
2017-11-01 to 2018-10-311,250,010USD365

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2018-11-01 to 2019-10-3199,095USD365
2017-11-01 to 2018-10-3174,601USD365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2018-11-01 to 2019-10-31526,567USD365
2017-11-01 to 2018-10-31435,527USD365

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2018-11-01 to 2019-10-314,062USD365
2017-11-01 to 2018-10-311,498USD365

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2018-11-01 to 2019-10-313,593,069USD365
2017-11-01 to 2018-10-31-1,158,809USD365

Inspect the source

Entity
PHARMA-BIO SERV, INC. / CIK 0001304161
Captured
2026-09-19T11:17:27.241Z
SEC response SHA-256
bc9f33e072a9daa74aa0e8c41fbfef83d107920bc25647db80386f28787f2d49

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001304161.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))